Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levamisole and Isoprinosine for COVID-19
NCT04383717Phase 3Unknown
- Sponsor
- Cairo University
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of levamisole and inosine pranobex in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Cairo University. Primary endpoints: COVID 19 induced fever at 4 weeks, COVID 19 induced dyspnea at 4 weeks and 2 more. Status: unknown.
02
Drugs
levamisoleinosine pranobex
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04383717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04383717.